Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Increases Purchase Price for Nanosphere

NEW YORK (GenomeWeb) – Luminex announced today that it has raised the purchase price for Nanosphere to $1.70 per share in cash from the $1.35-per-share price it originally offered for the molecular diagnostics developer.

This raises the share-price value of the transaction to approximately $77 million from $58 million.

Molecular diagnostics and life sciences research tools firm Luminex first announced its purchase agreement with Nanosphere in mid-May. At that time, the company also said it would pay or help Nanosphere pay $25 million in debt outstanding as of March 31. The deal was expected to close on or before July 1.

The increase came in response to an unsolicited bid from an unnamed third party, Luminex said. That company offered to buy Nanosphere for $1.50 per share.

Nanosphere's shares have climbed 27 percent to $1.67 in morning trading on the Nasdaq. Luminex's shares are up nearly 2 percent to $20.19.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.